rationalkat

rationalkat OP t1_jedzrqf wrote

An excerpt from the Paper:
 
"6 Broader Impacts:
Although the results presented in this paper are only on a research benchmark, if we extrapolate forward the capabilities of these models and methods, we anticipate vast broader impacts that have the potential to revolutionize numerous industries. By allowing LLMs to execute tasks on computers, our approach can enhance the capabilities of AI assistants and automation tools. This could lead to increased efficiency, reduced labor costs, and improved user experiences across any sector which uses computers to do work. We are most excited about gains in productivity in science and education, including AI research, which will lead to even faster development of new beneficial technologies and treatments."

20

rationalkat t1_iwwzd0z wrote

I highly recommend anyone here to watch the four-part presentation "The Great Transformation: The World in 2030" by Tony Seba. Especially the third part is right on topic; including a cost analysis for the US.

Part 1 - Patterns of Change, Key Technologies & #PhaseChangeDisruption
Part 2 - The Disruption of Transportation (EV+FSD enables TaaS (Transport as a Service) and will be 10x cheaper than owning a car)
Part 3 - The Disruption of Energy (Solar/Wind/Battery will be ~70% cheaper than today; and will replace any other source of energy)
Part 4 - The Disruption of Food & Agriculture (Precision Fermentation will have replaced livestock in ~ 12 years)

34

rationalkat t1_iv9krjq wrote

Some predictions for LEV:

11

rationalkat t1_issedrd wrote

We are getting there!

"Our process primarily tests single drugs to identify which drugs show potential, which is where our artificial intelligence/machine learning (AI/ML) comes into play. The AI/ML platform uses the drug sensitivity data—which drugs worked, and which did not—and the patient’s genomic profile to identify multivariate mechanisms driving drug sensitivity. By understanding those critical vulnerabilities, identifying drug combinations becomes a matter of matching FDA-approved, clinically available drugs to the tumor vulnerabilities. We can then use the AI/ML to inform combination design, which, alongside physician input on combinations of interest, guides follow-up combination drug testing. The AI/ML enables us to close the feedback loop in drug combination testing for any cancer patient."

13

rationalkat t1_iro4xk3 wrote

When you scroll down on the Metaculus-site, you can see the distribution of predictions.
Here is another source, that shows the division among ai researchers. I group them roughly into two camps; one camp believes AGI is imminent (arrives before 2040) and the other believes, that the current deep learning systems are a dead end and human-level AI is far away.

2

rationalkat t1_irmad02 wrote

Aubrey de Grey himself is also a computer scientist, who worked on AI before he switched to geroscience, so I would assume, that he is aware of the progress and the implications of the field of AI on research in general and longevity in particular. Whether other scientists in the longevity field are aware of the exponential progress in AI is hard to tell, but I doubt many are, when even a significant number of AI researchers themselves believe, that AGI is many, many decades away.

I personally don't think, that AI will be a necessity for the first generation of rejuvenation therapies, but will probably be essential in the development of next generation therapeutics afterwards. LEV is a long steady process, that will prolong our lifes with each generation by a decade or two, until we reach generation x, that will finally turn our bodies back into healthy, pristine twenty year old ones.

5